International Journal of Nephrology / 2017 / Article / Tab 4

Clinical Study

Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study

Table 4

(a) Mean medication dose in the treatment course of the denosumab group

Baseline3 months6 months12 months

CaCo3 (g/day)1.47 (15)1.65 (16)1.18 (15)1.32 (15)
Alfacalcidol (μg/day)0.31 (11)0.43 (11)0.34 (10)0.34 (11)
Calcitriol (μg/day)0.01 (1)0.03 (1)0.03 (1)0 (0)
Maxacalcitol (μg/week)5.0 (2)4.41 (2)2.94 (2)4.71 (3)
Cinacalcet (mg/day)2.94 (8)2.94 (10)2.94 (8)4.41 (9)

The number in the parentheses denotes the number of patients treated with each medication among the 17 patients.
(b) Mean medication dose in the treatment course in the control group

Baseline3 months6 months12 months

CaCo3 (g/day)1.50 (14)1.73 (15)1.10 (15)1.6 (15)
Alfacalcidol (μg/day)0.03 (2)0.01 (1)0.01 (1)0.01 (1)
Calcitriol (μg/day)0 (0)0 (0)0 (0)0 (0)
Maxacalcitol (μg/week)10.0 (7)8.75 (7)10.0 (6)10.0 (14)
Cinacalcet (mg/day)6.75 (16)11.25 (17)7.50 (17)11.25 (17)

The number in the parentheses denotes the number of patients treated with each medication among the 20 patients.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.